SynthesisHelicobacter2018
Helicobacter pylori infection reduces the risk of Barrett's esophagus: A meta-analysis and systematic review.
Synthesis in Helicobacter, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Effects of Helicobacter pylori infection on gastric cancer, obesity and esophageal diseases: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Helicobacter pylori infection is associated with reduced risk of Barrett's esophagus: a meta-analysis and systematic review.BMC gastroenterology · 2021Pooled it
- The relationship between metabolic syndrome and increased risk of Barrett's esophagus: an updated systematic review and meta-analysis.BMC gastroenterology · 2020Pooled it
- Association betweenBMJ open · 2020Pooled it
- Helicobacter pylori infection reduces the risk of Barrett's esophagus: A meta-analysis and systematic review.Helicobacter · 2018Pooled it
- Potential roles of Helicobacter pylori treatment, body mass index and waist circumference in the causation of erosive esophagitis: a randomized clinical trial (HEROES-GERD).International journal of obesity (2005) · 2020Trial
- Community assembly modeling of the microbiome within Barrett's esophagus and esophageal adenocarcinoma.BMC genomics · 2026Article
- Review
- Review
- Review
- Fecal microbial transplants as investigative tools in cancer.American journal of physiology. Gastrointestinal and liver physiology · 2024Review
- Effects and mechanisms ofWorld journal of gastroenterology · 2024Review
- Review
- Barrett's esophagus: results from an Italian cohort with tight endoscopic surveillance.Acta bio-medica : Atenei Parmensis · 2022Article
- Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Article
- Myths and misconceptions in the management ofFrontline gastroenterology · 2022Article
- Association of Barrett's esophagus withTherapeutic advances in chronic disease · 2022Article
- Review
- Global burden and epidemiology of Barrett oesophagus and oesophageal cancer.Nature reviews. Gastroenterology & hepatology · 2021Review
- The Meaning of Incidental Goblet Cells at the Gastroesophageal Junction.Digestive diseases and sciences · 2021Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe prevalence of Helicobacter pylori infection (HPI) has been decreasing in developed countries, with an increasing prevalence of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) at the same time. The aim of our meta-analysis was to quantify the risk of BE in the context of HPI.
methodsA systematic search was conducted in 3 databases for studies on BE with data on prevalence of HPI from inception until December 2016. Odds ratios for BE in HPI were calculated by the random effects model with subgroup analyses for geographical location, presence of dysplasia in BE, and length of the BE segment.
resultsSeventy-two studies were included in the meta-analysis, including 84 717 BE cases and 390 749 controls. The overall analysis showed that HPI reduces the risk of BE; OR = 0.68 (95% CI: 0.58-0.79, P < .001). Subgroup analyses revealed risk reduction in Asia OR = 0.53 (95% CI: 0.33-0.84, P = .007), Australia OR = 0.56 (95% CI: 0.39-0.80, P = .002), Europe OR = 0.77 (95% CI: 0.60-0.98, P = .035), and North-America OR = 0.59 (95% CI: 0.47-0.74, P < .001). The risk was significantly reduced for dysplastic BE, OR = 0.37 (95% CI: 0.26-0.51, P < .001) for non-dysplastic BE, OR = 0.51 (95% CI: 0.35-0.75, P = .001), and for long segment BE, OR = 0.25 (95% CI: 0.11-0.59, P = .001) in case of HPI.
conclusionsThis extensive meta-analysis provides additional evidence that HPI is associated with reduced risk of BE. Subgroup analyses confirmed that this risk reduction is independent of geographical location. HPI is associated with significantly lower risk of dysplastic, non-dysplastic, and long segment BE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.